<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04634435</url>
  </required_header>
  <id_info>
    <org_study_id>BHV1100-101 (formerly KP001)</org_study_id>
    <nct_id>NCT04634435</nct_id>
  </id_info>
  <brief_title>Autologous Memory-like NK Cell Therapy With BHV-1100 (Formerly KP1237), Low Dose IL-2 in Multiple Myeloma Patients</brief_title>
  <official_title>Phase 1 Study of Autologous Memory-like NK Cell Immunotherapy in Combination With KP1237 and Low Dose IL-2 as Early Post Autologous Transplant Consolidation in Minimal Residual Disease Positive, Newly Diagnosed Multiple Myeloma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biohaven Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Biohaven Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label single center Phase 1a/1b study with the primary objective of&#xD;
      establishing the safety and exploring the efficacy of infusing the ex vivo combination&#xD;
      product of cytokine induced memory-like (CIML) NK cells plus KP1237 and low dose IL-2 in&#xD;
      newly diagnosed MM patients who have minimal residual disease (MRD+) in first remission prior&#xD;
      to autologous stem cell transplant (ASCT).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 21, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicities following Combination Product dministration</measure>
    <time_frame>100 days post Combination Product administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of side effects related to the Combination Product</measure>
    <time_frame>100 days post Combination Product administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of MRD conversion from positive to negative</measure>
    <time_frame>90-100 days post-ASCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of MRD conversion from positive to negative</measure>
    <time_frame>1 year post-ASCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of MRD conversion from positive to negative during the maintenance phase</measure>
    <time_frame>Start of maintenance therapy 90-100 days post ASCT until disease progression (approximately 2-3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of PFS</measure>
    <time_frame>1 year post Combination Product administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of OS</measure>
    <time_frame>1 years post Combination Product administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response rate per the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma</measure>
    <time_frame>90-100 days post-ASCT, 1 year post-ASCT, and overall during maintenance phase (approximately 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of cytokine release syndrome per ASBMT consensus grading</measure>
    <time_frame>100 days post Combination Product administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of other Immune-related toxicities by CTCAE version 5.0</measure>
    <time_frame>100 days post Combination Product administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of the KP1237 by determining plasma Cmax</measure>
    <time_frame>4 days post Combination Product administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of the KP1237 by determining plasma Cmin</measure>
    <time_frame>4 days post Combination Product administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of the KP1237 by determining plasma AUC</measure>
    <time_frame>4 days post Combination Product administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of the KP1237 by determining plasma t1/2</measure>
    <time_frame>4 days post Combination Product administration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Newly diagnosed multiple myeloma patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Newly diagnosed MM patients who have minimal residual disease (MRD+) in first remission prior to autologous stem cell transplant (ASCT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>CIML NK Cells plus KP1237 and low dose IL-2</intervention_name>
    <description>Single dose infusion of CIML NK Cells plus KP1237 followed by low dose IL-2</description>
    <arm_group_label>Newly diagnosed multiple myeloma patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Had measurable disease according to Standard Diagnostic Criteria at the time of&#xD;
             initial Multiple Myeloma diagnosis&#xD;
&#xD;
          -  Meets criteria for symptomatic multiple myeloma at the time of induction chemotherapy&#xD;
&#xD;
          -  Is transplant eligible based on clinician judgement&#xD;
&#xD;
          -  Willing to undergo ASCT in first remission&#xD;
&#xD;
          -  Achieve partial response or better with induction chemotherapy prior to ASCT according&#xD;
             to the International Myeloma Working Group (IMWG) Uniform Response Criteria for&#xD;
             Multiple Myeloma&#xD;
&#xD;
          -  Be MRD+ disease upon restaging prior to stem cell collection and ASCT&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (EGOG) performance status score of less than 2&#xD;
&#xD;
          -  Life expectancy greater than six months&#xD;
&#xD;
          -  Have no evidence of active or decompensated heart failure, no recent history (past 6&#xD;
             months) acute myocardial infarction, no evidence of severe valvular disease and must&#xD;
             have a LVEF over 50% at the time of transplant evaluation&#xD;
&#xD;
          -  Adequate kidney function&#xD;
&#xD;
          -  No evidence of moderate/severe restrictive or obstructive lung disease at the time of&#xD;
             transplant evaluation&#xD;
&#xD;
          -  Adequate bone marrow function&#xD;
&#xD;
          -  Be willing to undergo CD34+ cell collection for stem cell transplant&#xD;
&#xD;
          -  Be willing to undergo leukapherisis&#xD;
&#xD;
          -  Adequate hepatic function&#xD;
&#xD;
          -  If of child-bearing potential, be willing to follow birth control and pregnancy&#xD;
             testing practice as recommended&#xD;
&#xD;
          -  Be willing to undergo bone marrow aspirate and biopsy as per treatment plan&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior autologous or allogeneic hematopoietic stem cell transplant&#xD;
&#xD;
          -  Prior cellular therapies, including NK cell therapy&#xD;
&#xD;
          -  Prior treatment with monoclonal antibodies&#xD;
&#xD;
          -  Prior treatment with melphalan&#xD;
&#xD;
          -  Prior treatment with immunosuppressive or immunomodulatory agents within 30 days of&#xD;
             enrollment&#xD;
&#xD;
          -  Disease progression at the time of enrollment&#xD;
&#xD;
          -  Non secretory multiple myeloma (defined as normal serum and urine immunofixation and&#xD;
             normal serum free light chain assay)&#xD;
&#xD;
          -  History of plasma cell leukemia at any time prior to enrollment&#xD;
&#xD;
          -  Patients seropositive for the human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Uncontrolled, Hepatitis C Virus or Hepatitis B Virus infection&#xD;
&#xD;
          -  Patient receiving other investigational or anti-myeloma drugs within 30 days of&#xD;
             enrollment&#xD;
&#xD;
          -  Patients with active clinically significant autoimmune diseases&#xD;
&#xD;
          -  Patients with active, clinically significant cancer other than multiple myeloma&#xD;
&#xD;
          -  Patients with neurological conditions that make difficult the assessment of neurologic&#xD;
             toxicity of the Combination Product&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sarah Ringuette</last_name>
    <phone>860-321-7002</phone>
    <email>sringuette@kleopharmaceuticals.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giada Bianchi, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 21, 2020</study_first_submitted>
  <study_first_submitted_qc>November 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2020</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cell Therapy</keyword>
  <keyword>CIML NK cell therapy</keyword>
  <keyword>cytokine induced memory-like natural killer cell therapy</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>antibody-dependent cell-mediated cytotoxicity</keyword>
  <keyword>ADCC</keyword>
  <keyword>CD38 positive</keyword>
  <keyword>CD38+</keyword>
  <keyword>plasma cells</keyword>
  <keyword>multiple myeloma</keyword>
  <keyword>hematological malignancies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

